Tag:

Sanofi

Latest Headlines

Latest Headlines

Gardasil dose reduction could boost EU sales for Merck-Sanofi joint venture

Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck and Sanofi--who market the HPV vaccine in Europe through joint venture Sanofi Pasteur MSD--will see the number of shots per patient fall.

Merck, Sanofi hope for sales expansion with two-dose Gardasil switch

Now that the European Commission has officially approved a two-dose Gardasil regimen for early teens, Merck and Sanofi will see the number of shots per patient fall. But that doesn't mean they'll necessarily take a sales hit, with the move potentially expanding overall access and providing a bump both drugmakers could use.

Sanofi and Pitt join up to test wannabe dengue blockbuster

Sanofi's dengue fever candidate is on the verge of regulatory applications after 20 years in the lab and more than $1.4 billion spent on R&D. Now the pharma giant has forged a new collaboration to help assess the jab's postintroduction effectiveness.

Sanofi beefs up social media channels with Spanish Twitter push

Sanofi has added a new Twitter handle to its Iberian lineup, @Sanofifarmacia, designed to create a pool of reference information and help community pharmacies in Spain promote their businesses.

Reckitt may top Novartis, Sanofi in $12B race for Merck consumer unit

With a final bid deadline looming, Merck & Co.'s consumer health unit still has several big-name pharma suitors. But Reckitt Benckiser, the Irish consumer specialist, may end up snatching the prize, Bloomberg reports.

After burning up $349M, CymaBay aims for Nasdaq as IPOs get shaky

Three years ago, Sanofi walked away from a $375 million diabetes partnership with Metabolex, which had just salved the wound with a new pact with J&J. Now, operating under a new name--CymaBay--and armed with a fresh $38 million raise from late last year, the small biotech is floating plans for a $30 million IPO, looking to cash in on the lingering biotech boom.

Sanofi misled investors with rosy Lemtrada predictions, lawsuit alleges

Sanofi investors are fed up with disappointing news on the multiple sclerosis drug Lemtrada. Vaunted as a potential blockbuster, the drug hasn't even made it to market in the U.S. Now, some investment funds are suing the French drugmaker, saying executives talked up Lemtrada in public--and kept bad news from the FDA private.

Sanofi decides to take a second shot on Lemtrada app

Sanofi is walking away from any plans to appeal the FDA's emphatic rejection of the multiple sclerosis drug Lemtrada, at least for now. But rather than launching the added trial that the FDA demanded ahead of any possible approval, the company thinks it has a shot at answering the FDA's concerns with a new application.

Sanofi sets sights on Africa with an eye on M&A

A few days after a similar announcement from GlaxoSmithKline, Sanofi said it plans to scale up its presence in Africa, looking to invest in marketing and R&D in response to the market's continued growth.

Sanofi CEO vows to 'go beyond' handouts, hit double-digit growth in Africa

Just days after GlaxoSmithKline announced it would open a new R&D lab and invest more than $200 million in Africa, Sanofi CEO Chris Viehbacher is affirming his country's devotion to Africa, too.